Edwards Lifesciences

JC Medical is a company focused on the design and development of transcatheter valve replacement products aimed at treating heart diseases. Its innovative systems are specifically engineered for the minimally invasive management of structural heart conditions, addressing critical issues associated with heart failure, including symptoms such as shortness of breath, fatigue, and chest pain. Notably, JC Medical's products incorporate a proprietary anchor mechanism that effectively addresses the needs of patients suffering from aortic regurgitation. This development not only enhances treatment efficacy but also offers a cost-effective solution for patients, making advanced cardiac care more accessible.

Genesis Medtech is a medical device company that develops a variety of products aimed at the value segment of the healthcare market. The company specializes in interventional devices for cardiology, oncology, peripheral vascular, and neurovascular applications. Its product range includes both surgical and interventional devices designed for enhanced placement accuracy and adaptability to diverse anatomical requirements. Additionally, Genesis Medtech offers ultrasonic energy devices and endoscopic linear cutting staplers. The company is committed to making quality healthcare affordable and accessible, particularly in emerging markets across the Asia Pacific region and beyond.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

Affluent Medical SA is a medical device company based in Paris, France, specializing in the design, development, manufacture, and marketing of innovative implantable prostheses. Founded in 2011, the company focuses on creating next-generation minimally invasive medical devices aimed at addressing severe health issues in urology and structural heart conditions. Its product portfolio features the Kardiozis prosthesis for noninvasive treatment of abdominal aortic aneurysms, the Kalios and Epygon implants for mitral valve repair and replacement, and the Artus implant, an electronically activatable artificial sphincter designed to treat severe urinary incontinence in both men and women. Affluent Medical's solutions are developed to enhance patient outcomes and improve the management of complex medical conditions.

Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

CAS Medical Systems is dedicated to the design and manufacture of innovative, non-invasive technologies and products vital to patient care in the most challenging clinical environments. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Harpoon Medical, Inc. is a medical device company based in Baltimore, Maryland, focused on developing and commercializing innovative transcatheter devices for patients with mitral valve disease. Founded in 2013, the company has pioneered a minimally invasive, image-guided surgical tool designed for repairing the mitral valve on a beating heart. This technology, developed at the University of Maryland School of Medicine, allows surgeons to perform repairs through a small incision between the ribs, eliminating the need for cardiac arrest or cardiopulmonary bypass. The Harpoon device utilizes a technique that involves inserting neochords to effectively eliminate mitral valve regurgitation. By streamlining the traditional open-heart surgical procedure, which typically lasts 3 to 6 hours, into a more efficient 60-minute operation, Harpoon Medical aims to significantly reduce recovery times, enabling patients to return to their normal activities much sooner. As a subsidiary of Edwards Lifesciences Corporation since 2017, Harpoon Medical continues to work towards transforming the treatment landscape for mitral valve disease.

Valtech Cardio Ltd. is a medical device company based in Or Yehuda, Israel, founded in 2006. It specializes in the development and manufacturing of cardiovascular devices aimed at treating mitral and tricuspid valve regurgitation through minimally invasive techniques. The company’s flagship products include the Cardioband System, which reconstructs the mitral valve via transfemoral direct annuloplasty, and the Cardiovalve system, designed for transfemoral transseptal mitral valve replacement. Additionally, Valtech offers the Cardinal, an adjustable annuloplasty ring that allows surgeons to optimize valve repair during surgery. The company is also advancing its pipeline with products like Cardioband Tricuspid, aimed at mitral regurgitation treatment, and the V-Chordal, which addresses mitral valve prolapse. Valtech Cardio operates as a subsidiary of Zeppelin Zox Ltd.

Endotronix Inc. is a medical technology company based in Lisle, Illinois, founded in 2007. It specializes in the development of advanced hemodynamic monitoring solutions aimed at improving the management of heart failure. The company’s flagship product is a miniaturized, wireless implantable pressure sensor that is designed to be used during interventional cardiovascular procedures. This sensor interfaces with an external measurement device and is part of a broader platform that includes a cloud-based disease management system. Through its innovative technology, Endotronix enables healthcare professionals to detect worsening heart failure earlier, facilitating proactive patient management and enhancing clinical outcomes. The company's approach connects patients, clinicians, and reimbursement teams, providing a comprehensive solution for outpatient hemodynamic management.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

CardiAQ Valve Technologies is a privately held company dedicated to advancing heart valve replacement procedures. Its primary focus is on developing innovative techniques for transcatheter mitral valve implantation (TMVI), aiming to enable physicians to implant mitral valves within a beating heart without the need for open-heart surgery.

CardioKinetix, Inc. is a medical technology company based in Menlo Park, California, specializing in the development of transcatheter implants aimed at treating heart failure. The company's flagship product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients suffering from ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, which may benefit millions of patients worldwide. CardioKinetix primarily serves customers in various countries, including the United States, France, Germany, and the United Kingdom. The company was incorporated in 2002 and is dedicated to advancing heart failure treatment through innovative technology.

Middle Peak Medical is a privately held medical device company dedicated to addressing mitral valve disease through innovative technology. The company develops a proprietary device designed for both percutaneous catheter-based interventions and minimally invasive or open-heart surgical procedures. This novel device specifically targets the treatment of mitral valve regurgitation, aiming to restore proper mitral valve function in cases of both functional and degenerative conditions. By providing a new posterior surface for the anterior leaflet to seal effectively, Middle Peak Medical seeks to meet critical unmet needs in the management of mitral valve diseases.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Embrella Cardiovascular, Inc. is a company based in Malvern, Pennsylvania, focused on developing innovative systems for embolic cerebral protection. Its primary goal is to assist interventionalists in minimizing the incidence of embolic strokes that can occur during cardiovascular procedures. By enhancing the safety and effectiveness of these interventions, Embrella Cardiovascular aims to improve patient outcomes and advance the field of cardiovascular medicine.

Embrella Cardiovascular, Inc. is a company based in Malvern, Pennsylvania, focused on developing innovative systems for embolic cerebral protection. Its primary goal is to assist interventionalists in minimizing the incidence of embolic strokes that can occur during cardiovascular procedures. By enhancing the safety and effectiveness of these interventions, Embrella Cardiovascular aims to improve patient outcomes and advance the field of cardiovascular medicine.

Myocor is a medical company based in Minnesota, founded in 1996, that specializes in developing and distributing therapeutic products aimed at treating mitral regurgitation and heart failure. The company focuses on creating medical devices that alter the physiology of heart failure, ultimately enhancing clinical outcomes for patients with late-stage heart conditions. One of its notable innovations is the Coapsys device, which utilizes pads and a tensioned string to reshape an enlarged heart and improve the functionality of a leaky mitral valve. By providing these advanced technologies, Myocor seeks to improve cardiac function and offer effective solutions for individuals suffering from heart-related ailments.

Whitland Research focused on the development of critical care monitoring technologies.

Vascular Architects Inc., established in 1997 by renowned surgeon Dr. Thomas J. Fogarty, specializes in designing, manufacturing, and marketing innovative devices for treating vascular stenoses, occlusions, and non-vascular obstructions. Their primary focus is on peripheral vascular disease, which involves reduced or lost blood flow due to narrowed or closed arteries. The company's product portfolio includes intraoperative vascular instruments like Doppler probes, laparoscopic Doppler systems, and oxygen analyzing monitors, used across various surgical specialties such as cardiovascular, urology, gynecology, neurology, and plastic surgery. Vascular Architects is led by an experienced team of technical, clinical, and business professionals, with key opinion leaders in interventional and vascular surgery communities serving on their Scientific Advisory Board.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Vascular Architects Inc., established in 1997 by renowned surgeon Dr. Thomas J. Fogarty, specializes in designing, manufacturing, and marketing innovative devices for treating vascular stenoses, occlusions, and non-vascular obstructions. Their primary focus is on peripheral vascular disease, which involves reduced or lost blood flow due to narrowed or closed arteries. The company's product portfolio includes intraoperative vascular instruments like Doppler probes, laparoscopic Doppler systems, and oxygen analyzing monitors, used across various surgical specialties such as cardiovascular, urology, gynecology, neurology, and plastic surgery. Vascular Architects is led by an experienced team of technical, clinical, and business professionals, with key opinion leaders in interventional and vascular surgery communities serving on their Scientific Advisory Board.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.